For those who believe in fundamentals, this stock is worth about 28 computed using the standard formula based on growth. Divide stock price by the stock's PEG ratio. 23.21 / .42 = 55.
Adjustment for cash and debt results in 28 per share valuation.
With the new FDA approval, the stock is likely to be worth north of 30.00 and we will see that after roll out.